Clinical trials: Psoriasis; Plaque
Moderate to Severe Plaque Psoriasis
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).
- Trial name
- BE CONNECTED (NCT04718896)
- Testing
- bimekizumab
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 41 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis
This study assessed the safety and pharmacokinetics (PK) of a single dose application of ARQ-151 cream 0.5% to 25 cm^2 of psoriatic plaque(s) (Cohort 1).
- Trial name
- NCT03392168
- Testing
- ARQ-151 cream 0.5%, ARQ-151 cream 0.15%, ARQ-151 vehicle cream
- Where
- 8 sites in United States, Canada
- Volunteers
- 91 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Plaque Psoriasis Vulgaris
Bioavailability of AZD0284 and IV Microtracer Study
The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.
- Trial name
- NCT03029741
- Testing
- AZD0284, [14C]AZD0284
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Psoriasis
Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept
This study proposes to compare 2 different methods for managing a subject with psoriasis who has achieved good disease control, as defined by a clinical response with a Physician Global Assessment (PGA) inferior or equal to 1 at…
- Trial name
- ReSPONSE (NCT00992394)
- Testing
- etanercept
- Where
- 46 sites in France, Germany and 7 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Psoriasis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
- Trial name
- PROTOSTAR (NCT03451851)
- Testing
- Guselkumab, Etanercept
- Where
- 39 sites in United States, Australia and 7 more
- Volunteers
- 120 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis.
- Trial name
- NCT03850483
- Testing
- PF-06700841
- Where
- 79 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- Pfizer
Plaque Psoriasis
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to determine the safety and efficacy of 2 doses of ABT-874 versus placebo in the treatment of subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT00570986
- Testing
- ABT-874
- Where
- 116 sites in United States, Canada
- Volunteers
- 1,465 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis, Immunomodulation
Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis
This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics.
- Trial name
- NCT01736696
- Testing
- tofacitinib
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Pfizer
Psoriasis
Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis
The primary objectives of this study are to evaluate the safety \& efficacy of consecutive treatments of Clobex® Spray and Silkis® Ointment in the management of plaque psoriasis.
- Trial name
- NCT00658788
- Testing
- clobetasol propionate spray 0.05%, calcitriol ointment
- Where
- 12 sites in United States
- Volunteers
- 305 people
- Sponsor
- Galderma R&D
Psoriasis
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
This study is a multicenter, randomized, double-blind, placebo- and active-controlled Phase III clinical trial sponsored by Nanjing Shunxin Pharmaceutical Co., Ltd., a subsidiary of Chiatai Tianqing Pharmaceutical Group.
- Trial name
- NCT07724366
- Testing
- TQH3906 capsules, Deucravacitinib tablets 6 mg
- Where
- 45 sites in China
- Volunteers
- 400 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Moderate to Severe Plaque Psoriasis
A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece
This study estimates the treatment goal achievement rate, depicts the implementation of the Progressive Psoriasis Initiative (PPI) recommendations regarding treatment modifications and transitioning, and assesses patient…
- Trial name
- CONCORDIA (NCT02713295)
- Where
- 43 sites in Greece
- Volunteers
- 273 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects
This is a multi-center, randomized, investigator-blinded, calcipotriol and betamethasone dipropionate gel and vehicle-controlled phase 3 clinical study to evaluate the efficacy and safety of MC2-01 cream in the treatment of…
- Trial name
- NCT07357831
- Testing
- MC2-01 cream, MC2-01 vehicle, CAL/BDP Gel
- Where
- 55 sites in China
- Volunteers
- 539 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Psoriasis
Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity
This is a phase IV, 12-month observational, prospective, open-label, multi-center study that will be conducted across approximately 50 sites in Canada for an estimated study duration of 32 months.
- Trial name
- CARE (NCT05132231)
- Testing
- Brodalumab, Matched cohort
- Where
- 42 sites in Canada
- Volunteers
- 394 people
- Sponsor
- Bausch Health Americas, Inc.
Moderate to Severe Plaque Psoriasis
P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses
- Trial name
- AMAGINE-2 (NCT01708603)
- Testing
- 210 mg brodalumab, 140 mg brodalumab, ustekinumab
- Where
- 153 sites in United States, Australia and 9 more
- Volunteers
- 1,831 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
- Trial name
- NCT02785159
- Testing
- IDP-118 Lotion, Tazorac Cream, IDP-118 Vehicle Lotion
- Where
- 14 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Plaque-type Psoriasis
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
This study is being conducted to evaluate the efficacy and safety/tolerability of SCH 900222/MK-3222 in a population of participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT01936688
- Testing
- MK-3222 200 mg, MK-3222 100 mg, Etanercept 50 mg
- Sponsor
- Sun Pharmaceutical Industries Limited
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
This was a 12-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis.
- Trial name
- Illuminate (NCT05896527)
- Testing
- DC-806
- Where
- 56 sites in United States, Canada and 6 more
- Volunteers
- 229 people
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Plaque Psoriasis
A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, dose-escalation Phase Ib study to evaluate the safety, tolerability, and pharmacokinetics of HB0017 following multiple dose in patients with moderate to severe plaque…
- Trial name
- NCT05442788
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Psoriasis
Clinical Trial to Investigate Efficacy of LAS41004 in Psoriasis
The aim of the study is to intra-individually compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT)
- Trial name
- NCT01283698
- Testing
- Experimental: LAS 41004 dosage 1, Experimental: LAS 41004 dosage 2, Experimental: LAS 41004 dosage 3
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis
This study will evaluate the efficacy and safety of Jiuweihuaban Pill in the treatment of moderate to severe plaque psoriasis(syndrome of blood-heat ).
- Trial name
- NCT06058546
- Testing
- low dose Jiuweihuaban Pill, high dose Jiuweihuaban Pill
- Where
- 12 sites in China
- Volunteers
- 180 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd